MyoKardia Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of MyoKardia, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – MYOK

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of MyoKardia, Inc. (NASDAQ: MYOK) to Bristol-Myers Squibb Company for $225.50 per share in cash is fair to MyoKardia shareholders. On behalf of MyoKardia shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

If you are a MyoKardia shareholder and would like to discuss your legal rights and options, visit MyoKardia Merger or contact Daniel Sadeh or Zachary Halper at [phone] or [e-mail] or [e-mail].

The investigation concerns whether MyoKardia and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to: (1) obtain the best possible consideration for MyoKardia shareholders; (2) determine whether Bristol-Myers is underpaying for MyoKardia; and (3) disclose all material information necessary for MyoKardia shareholders to adequately assess and value the proposed transaction.

If you are a MyoKardia shareholder and would like to discuss your legal rights and options, visit https://halpersadeh.com/actions/myokardia-inc-myok-stock-merger-bristol-myers/ or contact Daniel Sadeh or Zachary Halper at [phone] or [e-mail] or [e-mail].

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.